Drug Type Bispecific antibody, Biosimilar |
Synonyms Emicizumab Biosimilar (Prestige BioPharma Ltd.), IDC-2301, IDC2301 |
Target |
Action inhibitors |
Mechanism F10 inhibitors(Coagulation factor X inhibitors), factor IXa inhibitors(Factor IXa inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |



| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Hematologic Diseases | Preclinical | Singapore | 01 Apr 2025 |






